FutureChem퓨쳐켐

FutureChem is still deeply loss-making on trailing numbers, though its shares have bounced 15.7% over the past month after a steep one-year fall.

FutureChem, a Korean radiopharmaceutical developer, reported trailing twelve-month revenue of ₩20.6B but an operating loss of ₩9.4B and a net loss of ₩11.1B through H1 2026. The shares closed at ₩6,920 on 2026-10-22, down 63.4% over one year, with a market capitalisation of about ₩214B. The data does not include a fair value estimate, analyst views or any forward forecasts.

What stands out

• Revenue has grown from ₩11.8B in 2021 to ₩18.7B in 2025, but operating losses have persisted every year, with a 2025 operating margin of -41.5%.
• Trailing cash of ₩5.8B against borrowings of ₩2.1B and trailing free cash flow of -₩10.9B suggests the company relies on funding beyond its operations; the data does not say how it is financed.
• Price-to-book is 3.9 and price-to-sales is 10.4, while P/E is not meaningful because earnings are negative and no dividend is paid.
• Foreign ownership fell from 7.1% to 5.1% over the past 60 days, while institutions were net sellers over the last 20 days and foreign investors were small net buyers.
• Recent filings include a 'Major management matter relevant to investors' dated 2026-10-23, an ex-rights bonus issue on 2026-09-16, and several 5%+ holding and insider shareholding reports; the filings do not describe their content in the data.

What to watch

• The content of the 'Major management matter relevant to investors' filing dated 2026-10-23, which the data does not describe.
• The next periodic financial results, to see whether the operating loss narrows from the trailing ₩9.4B and whether cash keeps pace with negative free cash flow.
• Pipeline progress for its PSMA prostate cancer treatment and clinical trials in the US, Europe and China; the data contains no timelines or news on these.